Earnings Call Summary | AMBU A/S(AMBFF.US) Q2 2024 Earnings Conference
Earnings Call Summary | AMBU A/S(AMBFF.US) Q2 2024 Earnings Conference
The following is a summary of the Ambu A/S (AMBFF) Q2 2024 Earnings Call Transcript:
以下是Ambu A/S（AMBFF）2024年第二季度财报电话会议记录摘要：
Financial Performance:
财务业绩：
Ambu A/S reported Q2 organic revenue growth of 15.5%, majorly backed by the endoscopy business which saw a growth of 22.3%.
Operating profit margin before special items increased notably to 14.2% from 3.9% in the same quarter last year.
The company delivered strong free cash flow, amounting to DKK128 million for Q2.
The company's Q2 operating expense was stable at DKK619 million compared to the previous year. Despite investments, the OpEx ratio dropped almost 7 percentage points due to decreased distribution costs.
Ambu increased their revenue guidance for the full year from 7%-10% to 10%-12% and EBIT margin from 8%-10% to 10%-12%.
Ambu A/S报告称，第二季度有机收入增长了15.5％，这主要是由内窥镜业务增长22.3％的支持的。
不计特殊项目的营业利润率从去年同期的3.9％显著增长至14.2％。
该公司实现了强劲的自由现金流，第二季度达到 DKK128 百万英镑。
与去年相比，该公司第二季度的运营支出稳定在 DKK619 百万美元。尽管进行了投资，但由于分销成本的降低，运营支出比率下降了近7个百分点。
Ambu将全年收入预期从7％-10％上调至10％-12％，息税前利润率从8％-10％上调至10％-12％。
Business Progress:
业务进展：
Ambu gained two FDA approvals for new products in the gastroenterology portfolio and launched a broncosimulator for training in pulmonology.
Ambu reported solid growth in US and EMEA regions and foresees potential to convert the gastroenterology market to single-use endoscopy.
A consistent growth was seen in different sectors like anesthesia, patient monitoring, ENT, and urology.
The company announced continuation of investments for further growth and execution of the 'Zoom in strategy' for increasing EBITDA and improving EBIT margin.
Ambu has plans to maintain its leadership in the market despite increased competition by focusing on differentiation and sees potential for inorganic growth with careful consideration of mergers and acquisitions.
Ambu在胃肠病学产品组合中的新产品获得了两项美国食品药品管理局的批准，并推出了用于肺病学培训的支气管模拟器。
Ambu报告说，美国和欧洲、中东和非洲地区稳步增长，并预计有可能将胃肠病学市场转变为一次性内窥镜检查。
麻醉、患者监护、耳鼻喉科和泌尿外科等不同领域均出现持续增长。
该公司宣布继续投资以进一步增长并执行 “放大战略”，以增加息税折旧摊销前利润和提高息税前利润率。
尽管竞争加剧，Ambu仍计划通过专注于差异化来保持其在市场的领导地位，并在仔细考虑并购的情况下看到了无机增长的潜力。
Tips: For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.
提示：欲了解更多详情，请访问投资者关系网站。本文仅供投资者参考，不构成任何投资建议。
译文内容由第三方软件翻译。